Evogene (EVGN) director Nir details multiple stock option grants in Form 3

Rhea-AI Filing Summary

Evogene Ltd. director Nimrodi Nir filed an initial ownership report showing he holds several stock options to buy Evogene ordinary shares. These options carry exercise prices ranging from $1.29 to $11.00 per share and have expiration dates between 2030 and 2035.

One grant covering 10,000 underlying ordinary shares at an exercise price of $1.29 per share vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of its August 18, 2025 grant date. All reported holdings are listed as directly owned derivative securities rather than common shares.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Nimrodi Nir

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 5,625 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nimrodi Nir

(Last) (First) (Middle)

291 CHINQUAPIN AVE

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	07/21/2022	04/20/2030	Ordinary shares	5,625	$11	D
Stock Option (right to buy ordinary shares)	09/15/2023	09/15/2032	Ordinary shares	1,800	$10.2	D
Stock Option (right to buy ordinary shares)	05/11/2024	05/11/2033	Ordinary shares	1,800	$6.4	D
Stock Option (right to buy ordinary shares)	06/13/2025	06/15/2034	Ordinary shares	1,800	$6.6	D
Stock Option (right to buy ordinary shares)	(1)	08/18/2035	Ordinary shares	10,000	$1.29	D

Explanation of Responses:

1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Evogene (EVGN) director Nimrodi Nir report on this Form 3?

Nimrodi Nir reports his initial holdings of stock options to buy Evogene ordinary shares. The filing lists multiple option awards with specific exercise prices, expiration dates, and underlying share amounts, all held as derivative securities rather than currently owned common shares.

How many Evogene (EVGN) shares are covered by Nimrodi Nir’s lowest-priced options?

The lowest-priced options have an exercise price of $1.29 per share and cover 10,000 underlying ordinary shares. These options give the right, but not the obligation, to buy Evogene shares at that price before their stated expiration date in 2035.

What is the vesting schedule for Nimrodi Nir’s 10,000-share Evogene (EVGN) option grant?

The 10,000-share option grant vests in equal quarterly installments of 25%. According to the disclosure, it will be fully vested on the one-year anniversary of the August 18, 2025 grant date, meaning the entire grant becomes exercisable within that first year.

Are there any buy or sell transactions in this Evogene (EVGN) Form 3 filing?

No buy or sell transactions are reported. The Form 3 serves as an initial statement of beneficial ownership, listing existing stock option holdings for Nimrodi Nir, including exercise prices, expiration dates, and underlying share amounts, without showing any recent purchases or sales.

What are the exercise prices and expirations of Nimrodi Nir’s Evogene (EVGN) options?

The options have exercise prices of $11.00, $10.20, $6.40, $6.60, and $1.29 per share. Their expiration dates run from April 20, 2030 through August 18, 2035, defining how long each grant can be exercised.